Press release
Sarepta Therapeutics to Present at the UBS Biopharma Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced
About this update from Sarepta Therapeutics, Inc.
[{"type":"text","content":" CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the UBS Biopharma Conference on Thursday, Nov. 9, 2023 at 9:00 a.m. E.T. The fireside chat will be held at the Fontainebleau Miami Beach in Miami Beach, Fla.\n\n\nThe presentation will be webcast live under the Events & Presentations section of the investor relations section of Sarepta’s website at https://investorrelations.sarepta.com/events-presentations and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.\n\n\nAbout Sarepta Therapeutics\n\n\nSarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.\n\n\nInternet Posting of Information\n\n\nWe routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20231102269533/en/\n\nInvestor Contact:\nIan Estepan, 617-274-4052\[email protected]\n\n\nMedia Contact:\nTracy Sorrentino, 617-301-8566\[email protected]\n\n\nSource: Sarepta Therapeutics, Inc.","length":4932,"tagName":"div"}]